Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 1, 1996, Pages 144-148

  Halle, Martin ^a,b   Berg, Aloys ^a   Keul, Joseph ^a   Baumstark, Manfred W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Medizinische Klinik   (Germany)

Author keywords

coronary risk factors; fibrinogen; LDL subfractions

Indexed keywords

FATTY ACID; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DENSITY GRADIENT CENTRIFUGATION; DISEASE ASSOCIATION; ERGOMETRY; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0030070847     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.1.144     Document Type: Article

References (41)

1. Fisher WR. Heterogeneity of plasma low density lipoprotein manifestations of the physiologic phenomenon in man. Metabolism. 1983;32:283-291.
2. Shen MMS, Krauss RM, Lindgren FT, Forte TM. Heterogencity of serum low density lipoproteins in normal human subjects. J Lipid Res. 1981;22:236-244.
3. Foster DM, Chait A, Albers JJ, Failor RA, Harris C, Brunzell JD. Evidence for kinetic heterogeneity among human low density lipoproteins. Metabolism. 1986;35:685-696.
4. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density lipoprotein subtractions, determined by X-ray small-angle scattering. Biochim Biophys Acta. 1990;1037:48-57.
5. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 1991;90:67-80.
6. Austin MA, Breslow JL, Hennekens CH, Buring JE. Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
7. Austin MA, King MC, Vranizan K, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
8. Wilhelmsen L, Svärdsudd K, Korsan-Bcngtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
9. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
10. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
11. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti R, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
12. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitchead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1991;83:836-844.
13. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA. 1987;258:1183-1186.
14. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res. 1993;70:1-38.
15. Schultz DR, Arnold PI. Properties of acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 1990;20:129-147.
16. Giansante C, Fiotti N, Cattin L, Da Col PG, Calabrese S. Fibinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: relationships with other cardiovascular risk factors. Thromb Haemost. 1994;71:581-586.
17. Bara L, Nicaud V, Tiret L, Cambien F, Samama MM. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIc and PAI-1 in European offspring: the EARS study. European Atherosclerosis Research Study Group. Thromb Haemost. 1994;71:434-440.
18. Lindgren FT. Preparative ultracentrifugal laboratory procedures and suggestions for lipoprotein analysis. In: Perkins EG, ed. Analysis of Lipids and Lipoproteins. Champaign, III: American Oil Chemists' Society; 1975:204-224.
19. Halle M, Berg A, Frey I, König D, Keul J, Baumstark MW. Relationship of obesity with concentration and composition of LDL subfraction particles in normoinsulinemic men. Metabolism. 1995; 44:1384-1390.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
21. Winocour PH, Kaluvya S, Ramaiya K, Brown L, Millar JP, Farrer M, Neil AW, Laker MF, Alberti KG. Relation between insulinemia, body mass index, and lipoprotein composition in healthy, nondiabetic men and women. Arterioscler Thromb. 1992;12:393-402.
22. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. JAMA. 1986;256:2835-2838.
23. Brunzell JD, Sniderman AD. Albers JJ, Kwiterovich PO. Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis. 1984;4:79-83.
24. Miller NE, Hammet F, Saltissi S, Rao S, van Zeller H, Coltrat J, Lewis B. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J. 1981;282:1741-1744.
25. Salonen JT, Salonen R, Seppänen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subtractions, and the risk of acute myocardial infarction: a prospective population study in Eastern Finnish men. Circulation. 1991;84:129-139.
26. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32: 1741-1753.
27. Campos H, Genest JJ, Blijlevens E, McNamara JR. Jenner JL, Ordovas JM, Wilson PWF, Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992; 12;187-195.
28. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106:241-253.
29. Berg A, Frey I, Baumstark MW, Halle M, Keul J. Physical activity and lipoprotein lipid disorders. Sports Med. 1994;17:6-21.
30. Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP, Mayer EJ, Krauss RM. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation. 1993;88:381-387.
31. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990; 227;273-278.
32. Ganda OM, Arkin CF. Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care. 1992; 15:1245-1250.
33. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91:191-205.
34. Lee AJ, Smith WC, Lowe GD, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol. 1990;43:913-919.
35. Pilgeram LO, Pickart LR. Control of fibrinogen biosynthesis: the role of free fatty acid. J Atheroscler Res. 1968;8:155-166.
36. Halle M, Berg A, Baumstark MW. Differences in concentration and composition of LDL subfraction particles in hypercholesterolemic men with and without hypertriglyceridemia. Nutr Metab Cardiovasc Dis. 1993;3:179-184.
37. Goldberg IJ, Le NA, Ginsberg HN, Paterniti JR, Brown WV. Metabolism of apoprotein B in cynomolgus monkey: evidence for independent production of low density apoprotein B. Am J Physiol. 1983;244:E196-E201.
38. Berman M, Hall M, Levy RI, Eisenberg S, Bilheimer DW, Phair RD, Goebel RH. Metabolism of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteinemic subjects. J Lipid Res. 1978;19:38-56.
39. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation. 1992;86: 803-811.
40. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992;41(suppl 2);97-101.
41. Rokita H, Neta R, Sipe JD. Increased fibrinogen synthesis in mice during the acute phase response: co-operative interaction of interleukin 1, interleukin 6, and interleukin 1 receptor antagonist. Cytokine. 1993;5:454-458.